Saudi Arabia is expanding its ambitions in advanced therapies through Vision 2030, focusing on building local biomanufacturing capabilities and accelerating access to cell and gene therapies.

This discussion examines how next‑gen platforms and predictive modelling approaches provide the process insight to drive consistency, yield, and potency as programs move towards commercialization.

Vitrafy solves the challenge of inconsistent, manual, and hard-to-scale cryopreservation processes that can compromise cell quality and therapy outcomes.

This session is designed for cell and gene therapy developers, process development teams, and manufacturing leaders seeking to accelerate timelines while reducing manufacturing costs.

US biotech companies expanding clinical trials into the EU and UK face complex regulatory and logistics challenges. Damian Larington shares key requirements, common mistakes and emerging trial trends.

BBG Advanced Therapies has built infrastructure to both help developers access reliable high-quality starting material, as well as downstream support for testing, manufacturing, and logistics.

Excellos specializes in deep characterization of starting materials for adaptive immunotherapies for the better cellular immunotherapies as well as being flexibility in novel process development.

Teknova leverages their modular manufacturing platform to help novel therapy developers across cell and gene therapy, mRNA, and next-generation antibodies accelerate their breakthroughs.

Symcel addresses one of the biggest remaining bottlenecks in cell & gene therapy: QC release, through a breakthrough rapid, growth-based microbial detection system.

What if accelerating innovation and reducing risk were not opposing forces? This session looks at how the trade-off can be overcome from a CMC perspective.